Biomarin Pharmaceutical Inc. (1BMRN)
MTA
Closed
Aug 21, 2026
Day's Range
57.8852 wk Range
44.36Overview - 1BMRN - Biomarin Pharmaceutical Inc.
Key Statistics
Valuation
Enterprise Value
12.41B
P/E (Trailing)
‪180.87‬
PEG Ratio
‪-2.21‬
Price / Sales (TTM)
‪3.28‬
Price / Book
‪2.07‬
EV / EBITDA
‪22.51‬
Profitability
Gross Margin
‪79.50%‬
Profit Margin
‪2.14%‬
Operating Margin
‪21.16%‬
Return on Assets
‪3.25%‬
Return on Equity
‪1.18%‬
Ownership
Shares Outstanding
193.28M
Float
192.39M
Held by Insiders
‪0.34%‬
Held by Institutions
‪103.75%‬
Price stats
Beta
‪0.22‬
50-Day Avg
‪52.45‬
200-Day Avg
‪49.59‬
Dividends
Payout Ratio
‪0.00%‬
Market Cap - 1BMRN - Biomarin Pharmaceutical Inc.
Peers - 1BMRN - Biomarin Pharmaceutical Inc.
Peer Comparison
Compared with companies in Biotechnology listed on MTA.
- 1BMRNMTABiomarin Pharmaceutical Inc.10.22BMarket Cap+14.58%52-week change183.81P/E (Trailing)‪2.14%‬Profit Margin
- 1VRTXMTAVertex Pharmaceuticals Incorporated107.27BMarket Cap+27.82%52-week change32.13P/E (Trailing)‪34.99%‬Profit Margin
- 1REGNMTARegeneron Pharmaceuticals Inc.73.52BMarket Cap+28.94%52-week change20.57P/E (Trailing)‪27.86%‬Profit Margin
- 1ALNYMTAAlnylam Pharmaceuticals Inc45.81BMarket Cap-89.61%52-week change41.96P/E (Trailing)‪16.12%‬Profit Margin
- 1ALABMTAASTERA LABS INC COMMON STOCK (Ticker: 1ALAB)42.67BMarket Cap+47.15%52-week change140.57P/E (Trailing)‪30.74%‬Profit Margin
- 1INSMMTAInsmed Inc30.28BMarket Cap+16.20%52-week change-17.19P/E (Trailing)‪-76.94%‬Profit Margin
- 1CGMTAThe Carlyle Group Inc.18.64BMarket Cap-16.74%52-week change50.83P/E (Trailing)‪13.01%‬Profit Margin
Profile Summary - 1BMRN - Biomarin Pharmaceutical Inc.
About
BioMarin Pharmaceutical Inc. is a leading global biotechnology company specializing in the development and commercialization of therapies for people with serious and life-threatening rare genetic diseases. Its portfolio includes eight approved treatments targeting conditions such as mucopolysaccharidosis types I, IVA,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
